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It was with interest that I read the above paper. The
previous study by Rothwell et al.1 makes clear the sub-
groups of patients with symptomatic carotid stenosis
and who would benefit most and least from carotid
endarterectomy.
The conclusion by Naylor, Rothwell and Bell that
units should quote their own results for stroke/death at
30 days is extremely important. It is unjustified to apply
published results to other units unassociated with said
publications. Over the last two decades, most specialist
units have found a stroke/death risk in symptomatic
patients of approximately 2% validated by neurologists.
This comprises 0% ipsilateral stroke, but with MI death,
contralateral stroke and cerebral haemorrhage from
reperfusion, contributing to the overall 2%.
In the UK, with league tables now in fashion, it would
be useful for patients and doctors alike, if carotid
endarterectomies were publicly audited and published
as they were last year for aortic aneurysm repair.
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stenosis and who would benefit most and least from
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30 days is extremely important. It is unjustified to apply
published results to other units unassociated with said
publications. Over the last two decades, most specialist
units have found a stroke/death risk in symptomatic
patients of approximately 2% validated by neurologists.
This comprises 0% ipsilateral stroke, but with MI death,
contralateral stroke and cerebral haemorrhage from
reperfusion, contributing to the overall 2%.
In the UK, with league tables now in fashion, if would
be useful for patients and doctors alike, if carotid
endarterectomies were publicly audited and published
as they were last year for aortic aneurysm repair.
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The paper by Abidia et al.1 is interesting and
contributes to the evidence supporting the use of
hyperbaric oxygen (HBO) in the management of
diabetic foot ulcers.
Overall, the study was well constructed, and sought
to control a number of variables that have been
overlooked in the past; for example, the exclusion of
patients requiring vascular surgical reconstruction
and also the inclusion of an adequate period of careful,
expert wound dressing prior to HBO treatment. We
recognise in our practice that simply having patients
attend our unit for regular dressings can aid the
healing of these problem wounds.
It is refreshing to have a study with such a
comprehensive follow-up period, but we would like
to draw attention to the lack of significance in the
number of healed wounds at earlier time points.
Interestingly, the difference only becomes significant
when there is a recurrence of a previously healed ulcer
in the control group.
In addition, we feel that the use of the median as a
measure of central tendency is misleading and
inappropriate in this case. From the data given, the
mean reduction in ulcer size in the treatment group
cannot be more than 91.5% at the 6 week time point
and not more than 61.5% after 6 months, compared
with the reported median of 100%. It is stated in the
paper that the data was analysed on an intention to
treat basis. Those patients who did not complete the
study do not appear to have been included in the
results. For such a small data set it would not have
been unreasonable to include the raw data.
We would also question the adequacy of hyperbaric
air as a control treatment and disagree with the
suggestion that 50% oxygen is insufficient to produce
a clinical effect.
As discussed by the authors, a larger study would
further contribute to the body of evidence supporting
this treatment. We suggest using either normobaric air
or, under hyperbaric conditions, an oxygen partial
pressure equivalent to normobaric air as the control
group. This would enhance the difference between
groups and markedly increase the power of the study.
In addition, the outcome would be more directly
relevant to the traditional management of the diabetic
foot.
We appreciate that the logistical problems associ-
ated with this type of study are great, but we feel that
the use of a true control/sham group is within reach
and would add much more strength to research in the
hyperbaric field.
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